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Background: Transmissible gastroenteritis (TGE) is a highly contagious viral disease of swine, characterized by
severe vomiting, diarrhea, and high mortality. Currently, the vaccines for it are only partially effective and no specific
drug is available for treatment of TGE virus (TGEV) infection. RNA interference has been confirmed as a new
approach for controlling viral infections. In this study, the inhibitory effect of short hairpin RNAs (shRNAs) targeting
the ORF 7 gene of TGEV on virus replication was examined.
Results: Four theoretically effective sequences of TGEV ORF 7 gene were designed and selected for construction of
shRNA expression plasmids. In the reporter assays, three of four shRNA expression plasmids were able to inhibit
significantly the expression of ORF 7 gene and replication of TGEV, as shown by real-time quantitative RT-PCR
analysis of viral ORF 7 and N genes and detection of virus titers (TCID50/ml). Stable swine testicular (ST) cells
expressing the shRNAs were established. Observation of the cytopathic effect and apoptosis, as well as a cell
proliferation assay demonstrated that the three shRNAs were capable of protecting ST cells against TGEV
destruction, with high specificity and efficiency.
Conclusions: Our results indicated that plasmid-transcribed shRNAs targeting the ORF 7 gene in the TGEV genome
effectively inhibited expression of the viral target gene and viral replication in vitro. These findings provide evidence
that the shRNAs have potential therapeutic application for treatment of TGE.
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Transmissible gastroenteritis (TGE) is a highly conta-
gious viral disease of swine, characterized by severe
vomiting, diarrhea, and high mortality. These syndromes
are especially serious in neonatal piglets aged <2 weeks
old, frequently leading to a mortality as high as 100%;
even surviving older pigs generally show growth retard-
ation and low reward to feeding [1-3]. TGE causes
enormous economic loss annually worldwide. Currently,
several vaccines for prevention of TGE are available, but
their efficacy is variable. Both the attenuated and inacti-
vated vaccines are partially effective; attenuated TGE
virus (TGEV) vaccines have the risk of reverting to a
virulent form and may even induce an adverse reaction,* Correspondence: yanmingzhang76@yahoo.com
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reproduction in any medium, provided the orand the inactivated ones are poorly protective in swine
[4,5]. Moreover, newborn piglets infected with TGEV
may die within 1–4 days, whereas the vaccines for
TGEV do not provide effective protection at 7 days
after administration [6]. However, no cure for TGE is
presently available apart from symptomatic treatment.
RNA interference (RNAi) has been confirmed as a post-
transcriptional gene silencing mechanism, which is
widely considered to be the major antiviral system in
plants and insects [7,8]. The effective inhibition of repli-
cation of several RNA and DNA viruses in animal cells
also has been reported by means of RNAi [9-13]. There-
fore, RNAi may be developed as a potential therapy
for TGE.
TGEV is a member of the genus Alphacoronavirus in
the family Coronaviridae. It is a positive-sense, ssRNA
virus with a 28.5-kb genome that contains a leader
sequence at the 50 end and a poly(A) tail at the 30 end,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(E), membrane (M) and nucleoprotein (N)] and five
nonstructural proteins (replicase 1a, 1b, 3a, 3b and
protein 7) [14-16]. The genome itself, together with six
sub-genomic mRNAs transcribed discontinuously,
forms a nested set of RNAs of different lengths with
co-terminal ends [17].
ORF 7 is located at the 30 end of the genome. It
encodes a 78-amino-acid, 9.1-kDa hydrophobic protein,
and has been reported to play a role in the process of
membrane-associated replication complexes and/or
virion assembly [18,19]. Recently, more studies have
shown that the deletion of TGEV ORF 7 by reverse gen-
etics may be related to the viral virulent and promotes
an intensified dsRNA-activated host antiviral response
[14]. Compared to other viral proteins’ gene (such as
proteins S, E, M or N), the ORF7 region is relatively
conservative and RNAi targeting to ORF 7 gene will
result in the degradation of both the sub-genomic
mRNA for ORF 7 and the other sub-genomic mRNAs
[18,20]. Besides, data showed that the 3' end of TGEV
genome (ORF 7 gene and the downstream gene) could
interact with host cell proteins and played a positive role
in the replication of TGEV [21,22]. According to the
characteristics of RNAi, the downstream gene will be
degraded with the ORF 7 gene. Then the interaction of
3' end of TGEV genome and host cell proteins will be
interrupted and the viral replication will be reduced.
Thus, it is helpful to use RNAi against it as a new thera-
peutic option. Here, we demonstrate that RNAi targeting
of the ORF 7 gene of TGEV, introduced by short hairpin
RNAs (shRNAs), is capable of inhibiting virus replication
and protecting swine testicular (ST) cells from the
destruction induced by TGEV, which may be not only a
new anti-TGEV strategy, but also a new approach to the
study of its pathogenesis.
Results
Examination of shRNAs effect by real-time quantitative
RT-PCR
Relative quantifications of both the ORF 7 and N genes
were performed by real-time quantitative RT-PCR. Com-
parative threshold (Ct) cycle values in three independent
experiments were calculated by the Ct method, and the
average relative amount of ORF 7 gene in each sample is
represented in Figure 1. The relative amount of ORF 7
gene in mock control cells was regarded as 1.000, where
the relative amounts of ORF 7 gene in cells infected with
TGEV after being transfected with pGPU6-GFP/207,
pGPU6-GFP/238, pGPU6-GFP/241, pGPU6-GFP/276
and pGPU6-GFP/NC were 0.006, 0.474, 0.108, 0.124
and 0.892, respectively, and in cells infected with
TGEV before transfection was 0.050, 0.521, 0.212, 0.234
and 0.881, respectively. The sequence-specific shRNApGPU6-GFP/207 reduced the amount of ORF 7 gene by
approximately 99% and 95%, which was better than with
the other three plasmids.
Real-time quantitative RT-PCR of the N gene (Figure 2)
for cells infected with TGEV after transfection with those
shRNAs was 0.006, 0.471, 0.138, 0.230 and 0.762, respect-
ively. This indicated that these sequence-specific shRNAs
had approximately 99%, 53%, 86%, 77% and 24% reduc-
tions in TGEV genome (included sub-genomic mRNAs,
except the shortest one). Although the levels of viral gen-
ome in the cells infected with TGEV before being trans-
fected with shRNAs were 0.075, 0.600, 0.174, 0.256 and
0.819, corresponding to a 92%, 40%, 83%, 74% and 18%
reductions in TGEV RNA. Taken together, RNAi against
ORF 7 gene showed a dramatic reduction in the TGEV
viral.
Examination of shRNAs effect by infectious virus assay
The 50% tissue culture infective dose (TCID50) assay
was performed to examine the effect of siRNA on pro-
duction of viable virus. Figure 3 shows that the titers
of TGEV were 102.51, 104.48, 103.31, 103.54 and 106.83
TCID50/ml in cells infected with TGEV after being trans-
fected with pGPU6-GFP/207, pGPU6-GFP/238, pGPU6-
GFP/241, pGPU6-GFP/276 and pGPU6-GFP/NC at 48 h
post-infection, respectively, and the titers of TGEV in
cells infected with TGEV before being transfected with
shRNAs were 102.43, 104.40, 103.25, 103.35 and 106.49
TCID50/ml. These data indicated that RNAi against ORF
7 gene reduced the progeny virus production signifi-
cantly; pGPU6-GFP/207 showed a maximum inhibition,
whereas pGPU6-GFP/241 and pGPU6-GFP/276 showed
partial virus replication inhibition, with pGPU6-GFP/238
being the least effective shRNA.
Establishment of ST cell lines stably expressing shRNAs
Based on the results obtained by real-time quantitative
RT-PCR and determination of TCID50, cells stably
expressing pGPU6-GFP/207, pGPU6-GFP/241, pGPU6-
GFP/276 and pGPU6-GFP/NC were selected by using
G418 (pGPU6-GFP/238 abandoned). Green fluorescence
protein (GFP) was used as a reporter and cells were
screened until 90% of them showed green fluorescence.
As shown in Figures 4 and 5, a similar virus replication
inhibition trend was observed in the cell lines in com-
parison with the transiently transfected cells. The three
shRNA-expressing cells exhibited potent ability in silen-
cing TGEV RNAs, whereas cells expressing pGPU6-
GFP/NC showed a slightly nonspecific effect.
Examination of shRNA effect by cell proliferation assay
To study the protective effect of shRNAs against TGEV
destruction, the MTS cell proliferation assay was per-
formed on ST cells stably expressing shRNA plasmids.
Figure 1 Reduction in expression of TGEV ORF 7 mRNA levels by shRNAs directed against ORF 7 gene in ST cells. Real time RT-PCR
analysis of ORF 7 mRNA level was normalized to the corresponding β-actin in the same sample. The ORF 7 gene level in Mock controls was
assigned a value of 1 for each experiment. The mean of three repeat experiments performed in triplicate is shown, and error bars represent the
standard deviation (SD).
He et al. Virology Journal 2012, 9:176 Page 3 of 9
http://www.virologyj.com/content/9/1/176As the absorbance is proportional to the number of liv-
ing cells in culture, it was measured at 492 nm by using
an ELISA reader at 40 h post-infection (including 4 h
incubation with MTS). Mean OD492 of solutions in ST
cells stably expressing pGPU6-GFP/NC and in control
ST cells was 0.455 and 0.332, respectively, whereas in ST
cells expressing pGPU6-GFP/207, pGPU6-GFP/241 or
pGPU6-GFP/276 were 2.001, 1.707 and 1.772, respect-
ively (Figure 6). This showed that ST cells expressing
shRNAs, especially pGPU6-GFP/207, were protected
from TGEV destruction, leading to a significant increase
in living cells compared with cells stably expressing
pGPU6-GFP/NC, or ST control cells.Figure 2 Inhibition of TGEV RNA replication by shRNAs in ST cells. Th
shortest one) was measured by real-time RT-PCR of the N gene, which was
mean of three repeat experiments performed in triplicate is shown, and erExamination of shRNA effect by fluorescence microscopy
To further investigate the effect of shRNAs on protect-
ing ST cells against TGEV-induced destruction, the
cytopathic effect (CPE) and apoptosis of cells stably
expressing shRNAs were examined by fluorescence
microscopy. The apoptotic cells were characterized by
condensed nuclei, and were colored blue by fluorescent
dye Hoechst 33342, whereas the CPE in cells that chan-
ged from cell fusion to lysis, and thereby formed large
bodies, were stained red by propidium iodide (PI). As
shown in Figure 7, the negative control pGPU6-GFP/NC
had no apparent inhibitory effect on TGEV-induced
CPE and apoptosis, because many cells formed largee amount of viral genome (included sub-genomic mRNAs except the
normalized to the corresponding β-actin in the same sample. The
ror bars represent the SD.
Figure 3 Reduction in titers of TGEV in ST cells transfected with shRNA plasmids. TCID50 values are the means of three repeat titrations,
and error bars represent the SD.
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expressing pGPU6-GFP/207 had few condensed nuclei,
and almost all cells expressing pGPU6-GFP/207 were
capable of maintaining CPE resistance, because there
were no apparent PI-stained cells. However, a small area
of mild CPE was seen in the cells expressing pGPU6-
GFP/241 and pGPU6-GFP/276, indicating that these
plasmids were less effective than pGPU6-GFP/207 at
protecting ST cells against TGEV-induced destruction.
Discussion
Although several veterinary coronavirus vaccines are
currently available, their efficacy is variable. Among
them, the infectious bronchitis virus vaccine is very ef-
fective for chickens [23], whereas the canine and porcine
vaccines are only partially effective. Furthermore, thereFigure 4 Reduction in expression of TGEV ORF 7 and N gene mRNA l
and N gene mRNA level was normalized to the corresponding β-actin in th
triplicate is shown, and error bars represent the SD.is currently no effective antiviral treatment against these
virus infections [24]; therefore, rapid and potent anti-
TGEV therapeutic agents are urgently needed. RNAi
technology provides an important methodology for
rational drug design and gene therapy for many viral dis-
eases, which has proven to be a potent tool for host
protection against viral infection, suppression of viral
genome transcription, and blocking viral replication
[25,26]. RNAi can be introduced into the cells using two
different approaches. The first is chemically synthesized
siRNAs. Cells transfected with chemically synthesized
siRNAs can achieve rapid and effective silencing of a tar-
get gene, but the effects are transient. Second, shRNAs,
which can be cleaved by Dicer to produce siRNAs in the
host cell, can circumvent the disadvantages of chemically
synthesized siRNAs by using stably transfected plasmidsevels in shRNAs expressing cells. Real time RT-PCR analysis of ORF 7
e same sample. The mean of three repeat experiments performed in
Figure 5 Reduction in titers of TGEV in ST cells stably expressing shRNAs. TCID50 values are the means of three repeat titrations, and error
bars represent the SD.
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the use of RNAi against TGEV via shRNA-expressing
plasmid vector pGPU6-GFP, which significantly reduced
viral genomic RNA replication and protected ST cells
from TGEV destruction, by targeting ORF 7 gene.
RNAi is highly sequence-specific and requires 100%
identity between the target and targeting sequences to
achieve virus clearance from cell culture [30-32]. The
application of shRNAs targeting the conserved region of
the gene is one way to overcome the lack of knowledge
of the target sequence. To ensure that shRNAs can be
used for a wide range of virus strains, we evaluated the
cross-inhibitory capabilities of these shRNAs by con-
ducting multiple alignments of TGEV ORF 7 gene
sequences, based on the available sequences in GenBank.
Our results showed that pGPU6-GFP/207, pGPU6-GFP/
241and and pGPU6-GFP/276 could cover 95% (19/20),
75% (15/20) and 75% (15/20) of TGEV strains, respect-
ively (data not shown). Interestingly, we have also con-
ducted multiple alignments of the sequences among
TGEV, feline coronavirus virus and canine coronavirus,
and have shown that they are also conservative. This
conservative characteristic of the sequences between theFigure 6 shRNA effect on protection of ST cells by MTS assay. The MT
line stably expressing the shRNA. OD values represent the mean± SD of ththree viruses means that they have greater potential
application for the treatment of the diseases caused by
these viruses, which also indicates that further studies
are necessary to search for the cross-inhibitory effects in
a range of TGEV strains and other coronaviruses.
In our study, two strategies were used to detect the in-
hibitory effect of shRNAs on both the ORF 7 gene and
TGEV genome. The first approach was that cells were
infected with TGEV after being transfected with shRNAs,
in which the shRNAs were used as preventive sub-
stances. As shown in Figures 1 and 2, there was a
marked decrease in both the ORF 7 and N genes, which
could be amplified simultaneously from all the same
regions within the TGEV genome RNA and sub-genomic
mRNAs (except the shortest one). The reduction showed
that the viral genome RNA and its transcripts were
decreased significantly. A similar suppression pattern
was observed for virus titers. In the second strategy,
shRNAs of ORF 7 gene were used as therapeutic agents
and transfected after the cells were infected with TGEV.
Almost all the cells maintained their normal morphology
before they were collected for real-time RT-PCR. The
ORF 7 and N genes were reduced significantly when theS assay was used to evaluate the viable cell numbers of each ST cell
ree separate experiments performed six times.
Figure 7 Effect of shRNAs on protecting ST cells against TGEV-induced destruction. ST cells stably expressing shRNAs infected with TGEV at
200 TCID50 were incubated with Hoechst 33342 (10 ng/ml) and PI (10 ng/ml) at 30 h after infection. The experiment was performed in triplicate
and repeated for three times.
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(Figures 1 and 2). More experiments were carried out at
8 and 12 h after TGEV infection, but the results were
not as remarkable as those after 4 h (data not shown),
which indicates that shRNAs affect the initial stage of
TGEV infection.
In the study by Ortego et al., recombinant TGEV with
ORF 7 gene deletion replicated in cell culture with simi-
lar efficiency to the wild-type virus, and stably main-
tained the modifications introduced into the genome
[22]. This observation seems to contrast with the results
of the present study, which provides evidence that RNAi
of the ORF 7 gene could lead to decreased virus replica-
tion. There are three possible reasons for this. First, the
genome of parental TGEV could be degraded directly
because it consists of a positive-sense ssRNA. Second, all
the other sub-genomic mRNAs could be degraded as the
ORF 7 gene is included in all the sub-genomic mRNAs.
As shown in Figures 2 and 4, N gene was significant
decreased in the shRNA expressing cells. Besides, the 30end of the TGEV genome gene, the downstream gene of
ORF 7 gene, could be degraded with the ORF 7 gene
according to the characteristics of RNAi, and its degrad-
ation could delay the viral replication, because it has
been reported that it could interact with host cell pro-
teins and have a great influence on the replication of
TGEV [21]. In the study by Cruz et al., it was reported
that TGEV without ORF 7 enhanced virulence in
infected piglets [14]. We speculate that this phenomenon
won’t happen on the RNAi treated pigs, because the
RNAi method is different from the reverse genetics tech-
nique. By the RNAi used in this study, the other viral
sub-genomic mRNAs were degraded (Figure 2 and 4).
While the reverse genetics deletion will only affect the
ORF 7 gene itself. Nevertheless, whether the technology
could be used in vivo still needs more explored.
To elucidate the protection of shRNAs against TGEV
in more detail, ST cells stably expressing the shRNAs
were established. TGEV replication in these cells was
observed through detection of virus titers and real-time
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showed 99% inhibition in the viral genome, whereas
pGPU6-GFP/241 showed up to 89% and pGPU6-GFP/
276 85% inhibition (Figure 4). TGEV destroys ST cells
in two ways, by apoptosis and necrosis [33,34]. There-
fore, CPE and apoptosis were analyzed. Examination of
TGEV-induced CPE indicated that ST cells were very
sensitive to TGEV infection. Cells expressing pGPU6-
GFP/NC formed large bodies and were stained red by PI
(Figure 7), whereas cells expressing pGPU6-GFP/207
were not stained red, indicating that the cell mem-
brane was intact. Compared with the condensed, irre-
gular nuclei of pGPU6-GFP/NC-expressing cells, cells
expressing pGPU6-GFP/207 were completely protected
from apoptosis and the nuclei showed normal morph-
ology. The sequence-specific shRNAs, especially pGPU6-
GFP/207, exhibited potent ability to protect ST cells
from TGEV-induced destruction. Our present results in-
dicate a close relationship between inhibition of TGEV
replication and cell viability by shRNAs. Our data also
suggest that siRNA targeting ORF 7 gene can elicit viral
RNA from infected cells and potentially offers an effi-
cient therapeutic option for TGEV infection.
Conclusions
Taken together, our results indicate that plasmid-
transcribed shRNAs targeting the ORF 7 gene in the
TGEV genome can inhibit expression of viral target
genes and viral replication in ST cells. This method
merits further investigation in animal studies to define
its therapeutic potential, and whether the technology




ST cells were cultured in high-glucose Dulbecco’s modi-
fied Eagle’s medium (DMEM; GIBCO, UK) containing
10% heat-inactivated fetal calf serum (HyClone, China)
and antibiotics (100 μg/ml streptomycin and 100 U/ml
penicillin); the culture medium was replaced every
3 days. TGEV H16 strain was obtained from the
National Control Institute of Veterinary Bioproducts
and Pharmaceuticals (Beijing, China) and propagated in
ST cells.
shRNA sequence selection and plasmid construction
Sequences from the ORF 7 gene of TGEV H16 strain
(GenBank accession no: FJ755618) were designed based
on the website siRNA designing tools (http://www.
ambion.com/techlib/misc/siRNA_finder.html and https://
rnaidesigner.invitrogen.com/rnaiexpress/). The sequences
were analyzed by BLAST to ensure that they did not
have significant nucleotide sequence homology with theswine genome, but shared 100% identity with the other
published sequences of TGEV strains, from which four
theoretically effective sequences at nucleotide positions
28187–28207 (ORF 7–207), 28218–28238 (ORF 7–238),
28221–28241 (ORF 7–241) and 28256–28276 (ORF 7–
276) were selected. A nonspecific sequence (NC) was
also scanned by BLAST analysis and served as a negative
control. These five sequences are listed in Table 1. All
the sequences were arranged in the following align-
ment: BbsІ+ Sense + Loop +Antisense +Termination sig-
nal +BamHІ and cloned into the pGPU6-GFP vector to
make shRNA expressing plasmids: pGPU6-GFP/207,
pGPU6-GFP/238, pGPU6-GFP/241, pGPU6-GFP/276
and pGPU6-GFP/NC.TGEV infection of transfected ST cells
Twenty-four hours before being transfected, ST cells
were seeded into six-well dishes in high-glucose
DMEM+10% fetal bovine serum (FBS) without antibio-
tics. When they reached 60–70% confluence, cells were
transfected with 4 μg/well pGPU6-GFP/207, pGPU6-
GFP/238, pGPU6-GFP/241, pGPU6-GFP/276 and
pGPU6-GFP/NC by Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
recommendations. After being incubated at 37°C for 4 h,
the transfection complex was removed and the medium
was replaced by high-glucose DMEM with 5% FBS. The
cells were inoculated with TGEV at 200 TCID50 24 h
later. The plasmids contained the GFP gene sequence.
Therefore, GFP was expressed allowing a good discrim-
ination between transfected and non-transfected cells.
The transfection efficiency was determined by monitor-
ing the percentage of GFP-expressing cells within the
live cell population, and it showed that nearly 80% of the
transfected cells were positive. CPE was evaluated and
the cell images were captured under an inverted fluores-
cence/phase-contrast microscopy (Nikon, Japan) at dif-
ferent time points post-infection. The cell cultures were
collected for a real-time quantitative RT-PCR analysis at
40 h post-infection.
He et al. Virology Journal 2012, 9:176 Page 8 of 9
http://www.virologyj.com/content/9/1/176shRNA transfection in TGEV-infected ST cells
One-day-old ST cells (60–70% confluence) were infected
with TGEV at 200 TCID50, and 4 h later, the transfection
complex of the shRNA-expressing plasmids (4 μg/well)
was added to each well and incubated for 4 h. The
medium was replaced by high-glucose DMEM+5% FBS,
and the cells were further incubated at 37°C in a 5%
CO2 atmosphere. Cell images were captured and the
cell cultures were collected for real-time quantitative
RT-PCR analysis at 40 h post-infection.
Total RNA extraction and real-time quantitative RT-PCR
To investigate the effect of the plasmid-transcribed
shRNAs on TGEV ORF 7 gene, TGEV-infected ST cells
were collected 40 h after viral infection. Total RNA was
isolated by Trizol phenol–chloroform extraction (Invi-
trogen) and ethanol precipitation, following the manu-
facturer’s recommendations. A real-time quantitative
RT-PCR was conducted by using a SYBR ExScript™ RT-
PCR Kit (Takara Bio, Dalian, China), according to
manufacturer’s instructions. The following two pairs of
primers: forward, 50-TTGCTCGTCCTCCTCCATGC-30
and reverse, 50-CCACTTTTAGTAATCTGGTTTCTGC-30
for TGEV ORF 7 gene; forward, 50-CGTCCACCG
CAAATGCTTC-30 and reverse, 50-AACCGACTGCTGT
CACCTTCAC-30 for β-actin gene. PCR was performed
in an iQ5 Real-Time PCR Detection System (Bio-Rad,
USA). Following a denaturation step at 95°C for 10 s,
42 cycles of amplification were performed at 95°C for
5 s, 58°C for 10 s, and 72°C for 15 s. Data were analyzed
according to the Ct method, where the amount of RNA
in samples normalized to β-actin and the tests was deter-
mined in triplicate.
To assess the influence of shRNAs on TGEV replica-
tion, the N gene of TGEV was used as a standard for the
TGEV genome. Another pair of primers was synthesized
for quantification of the TGEV genome in real-time RT-
PCR: forward, 50- GGAAGATGGCGACCAGATAG-30
and reverse, 50- CCACTTCTGATGGACGAGCA-30. Total
RNA of culture supernatants was isolated as described
above, and a real-time quantitative RT-PCR was con-
ducted using a SYBR ExScript™ RT-PCR Kit (Takara Bio),
according to the manufacturer’s instructions. Real-time
RT-PCR was performed and the procedure was similar
to that described above, expect that the reaction
temperature for annealing was 60°C. Data were analyzed
according to the Ct method, and the tests were per-
formed in triplicate.
Virus titration
TGEV cultures in siRNA-transfected cells were collected
48 h after viral infection. After three freeze–thaw cycles,
the cultures were serially diluted 10-fold from 10–1 to
10–10, and added to ST cells at 50–60% confluence in96-well plates. Each dilution was added to four wells.
After 3 days of infection, the TCID50 was calculated by
the Reed–Muench method.
Establishment of ST cell lines stably expressing shRNAs
The pGPU6-GFP vector carries the neomycin resistance
gene; therefore, ST cells stably expressing shRNAs were
selected using G418. GFP in the plasmids was used as a
reporter during the selection efficiency analysis. The ST
cells were seeded into six-well plates 24 h before being
transfected (up to 60–70% confluence). Cells were trans-
fected with pGPU6-GFP/207, pGPU6-GFP/241, pGPU6-
GFP/276 and pGPU6-GFP/NC by Lipofectamine 2000
as described before, and propagated in selection medium
containing 1500 μg/mlG418 until 90% of the surviving
cells stably expressed GFP.
MTS assay
ST cells stably expressing pGPU6-GFP/207, pGPU6-
GFP/241, pGPU6-GFP/276 and pGPU6-GFP/NC were
seeded in 96-well plates at 50–60% confluence and chal-
lenged with TGEV at 200 TCID50. Cell viability was
assessed by adding 20 μl/well of MTS (Promega, USA)
to cell cultures, according to the manufacturer’s instruc-
tions, at 36 h after viral infection. After incubation with
MTS for 4 h, light absorbance of each well was mea-
sured at 492 nm. Each measurement was performed six
times, and the experiment was repeated three times.
Fluorescence microscopy
ST cells stably expressing shRNAs were seeded in six-
well tissue culture plates at 50–60% confluence and
challenged with TGEV at 200 TCID50. Thirty hours after
infection, the cells were washed with Hank’s balanced
salt solution (HBSS) and incubated with Hoechst 33342
(10 ng/ml) at 37°C for 15 min, and then washed three
times with HBSS. Cell were then incubated with PI
(10 ng/ml) at 37°C for 15 min and washed with DMEM
without serum. Images were viewed by fluorescence
microscopy (Nikon, Japan).
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